Publications

• 2022 Nov 8 -12 SITC 2022 (poster 632)

  Clinical Update from a Phase 1, First-in-Human, Open-label Single Agent Study of SUPLEXA Therapeutic Cells in Patients with Metastatic Solid Tumors and Hematologic Malignancies

  View Conclusion & Download
• 2022 Oct 21-24 AACR Special Conference (poster B63)

  Exploratory immune phenotyping of longitudinal blood samples from the first-in-human phase 1 clinical trial of a novel autologous cellular therapy in patients with metastatic solid tumors

  View Conclusion & Download
• 2022 April 12 AACR Conference (poster 3599)

  Interleukin-10 and transforming growth factor-b do not suppress tumor killing activity of PBMC-derived SUPLEXA cells

  View Conclusion & Download
• 2021 November 15 SITC conference (poster 164)

  Potent Tumor Organoid Infiltration and Killing by PBMC Derived Effector Cells

  View Conclusion & Download
• 2019 Nov 6-10 Society for Immunotherapy of Cancer (SITC) conference

  Conversion of peripheral blood mononuclear cells into tumor-specific cytolytic cell populations using tumor cells engineered with multiple immunomodulatory factors

  View Conclusion & Download
• 2021 Mar 24-25 Innate Killer Cell conference

  A Differentiated and Broadly Applicable Autologous Whole Blood Derived Adoptive Cellular Therapy for Treating Cancer

  View Conclusion & Download
• 2021 Mar 26-29 ISCT conference

  Characterization of a Novel Autologous Pan-Cancer Cellular Immunotherapy

  View Conclusion & Download
• 2021 Apr 9 AACR conference (poster 1772)

  Development of PBMC derived tumor effector cells with potent pan-cancer cytolytic activity for autologous cellular immunotherapy

  View Conclusion & Download
• 2021 April 9 AACR conference (poster 1531)

  A novel approach for autologous pan-cancer cellular immunotherapy reveals dramatic expansion of αβ and γδ TCR T cell clonotypes indicative of an antigen-driven response

  View Conclusion & Download
• 2021 June 4-8 ASCO Conference (poster 7517)

  Engineered immunostimulatory cells can convert PBMCs from chronic lymphocytic leukemia (CLL) patients into potent tumor killing immune cells.

  View Conclusion & Download